case_images: PMC5170902_01
case_images: PET CT Imaging of Patient Undergoing Combination Ipilimumab/Nivolumab Immunotherapy. a
  left arrow, mesenteric lesion. right arrow, left upper extremity cutaneous lesion (1) prior to initiating combination ipilimumab/nivolumab therapy, (2) following the second dose of combination ipilimumab/nivolumab therapy. b (1) prior to initiating combination ipilimumab/nivolumab therapy, (2) following the second dose of combination ipilimumab/nivolumab therapy, (3) 1 year following the third dose of combination ipilimumab/nivolumab therapy and treatment discontinuation due to toxicity
case_images: 40425_2016_196_Fig1_HTML.jpg
case_images: PMC5170902_01_40425_2016_196_Fig1_HTML.jpg
case_images: Fig1
case_images: Repeat imaging with PET CT performed at that time confirmed prior FDG avid lesions involving the upper and lower extremities along with the small bowel lesion (Fig. 1). Repeat imaging with PET CT in March of 2014 showed complete resolution of the left upper extremity nodule and small intestine lesions and decreased size and FDG avidity of the left gastrocnemius lesion (Fig. 1).
case_images: Time line of clinical events
case_images: 40425_2016_196_Fig2_HTML.jpg
case_images: PMC5170902_01_40425_2016_196_Fig2_HTML.jpg
case_images: Fig2
case_images: He received his first infusion in January of 2014, returning 2 weeks later with a diffuse grade 3 skin rash, tachycardia, and reports of hot flashes (Fig. 2).